Alembic Pharmaceuticals Ltd

Alembic Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Pharmaceuticals Ltd

₹ 554 0.00%
05 Jun 2:51 p.m.
alembic-india.com BSE: 533573 NSE : APLLTD
About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Key Points

Leading Pharma company[1] Alembic is among the top 25 players in domestic formulations market. The company has a portfolio of about 200 formulation brands, of which three are among the top 300 domestic formulation brands in India. It has a share of 1.5% in the domestic market.

Website BSE NSE
  • Market Cap ₹ 10,887 Cr.
  • Current Price ₹ 554
  • High / Low ₹ 758 / 462
  • Stock P/E 31.8
  • Book Value ₹ 222
  • Dividend Yield 1.81 %
  • ROCE 7.33 %
  • ROE 7.12 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 35.9%

Cons

  • Tax rate seems low
  • Debtor days have increased from 48.9 to 67.6 days.
  • Promoter holding has decreased over last 3 years: -3.36%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
1,207 1,341 1,457 1,314 1,280 1,326 1,292 1,272 1,416 1,262 1,475 1,509 1,406
879 934 1,014 949 960 1,090 1,054 1,030 1,268 1,247 1,244 1,274 1,203
Operating Profit 328 407 443 365 320 236 239 242 148 15 231 235 204
OPM % 27% 30% 30% 28% 25% 18% 18% 19% 10% 1% 16% 16% 14%
-10 0 3 3 25 2 21 19 10 1 0 0 1
Interest 8 7 4 2 3 2 5 4 7 9 12 15 14
Depreciation 44 42 44 47 51 53 55 56 123 67 68 67 74
Profit before tax 266 360 398 318 292 183 200 201 29 -60 151 154 116
Tax % 23% 19% 18% 19% 19% 19% 20% 14% 24% 2% 12% 21% -31%
Net Profit 204 293 325 286 242 158 164 172 22 -66 133 122 153
EPS in Rs 11.93 15.99 16.96 14.88 12.75 8.37 8.34 8.74 1.12 -3.35 6.78 6.20 7.76
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
1,465 1,520 1,863 2,056 3,166 3,105 3,131 3,935 4,606 5,393 5,306 5,653
1,246 1,268 1,506 1,653 2,159 2,490 2,488 3,061 3,383 3,913 4,432 4,975
Operating Profit 219 252 358 403 1,007 615 643 874 1,223 1,480 874 677
OPM % 15% 17% 19% 20% 32% 20% 21% 22% 27% 27% 16% 12%
13 4 4 4 7 2 7 9 -39 87 50 3
Interest 38 15 10 4 5 5 3 18 27 16 18 50
Depreciation 34 35 40 44 72 83 105 115 157 183 287 275
Profit before tax 161 206 311 359 936 529 541 749 1,000 1,368 620 355
Tax % 19% 20% 24% 21% 23% 23% 22% 21% 20% 19% 17% 4%
Net Profit 130 165 236 283 720 403 413 583 801 1,146 521 342
EPS in Rs 6.90 8.77 12.49 15.01 38.20 21.39 21.89 31.00 43.97 58.33 26.50 17.40
Dividend Payout % 20% 29% 24% 23% 9% 19% 18% 18% 23% 24% 38% 46%
Compounded Sales Growth
10 Years: 14%
5 Years: 13%
3 Years: 7%
TTM: 7%
Compounded Profit Growth
10 Years: 8%
5 Years: -4%
3 Years: -26%
TTM: -34%
Stock Price CAGR
10 Years: 14%
5 Years: 5%
3 Years: -13%
1 Year: -24%
Return on Equity
10 Years: 21%
5 Years: 17%
3 Years: 14%
Last Year: 7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
38 38 38 38 38 38 38 38 38 39 39 39
Reserves 357 465 638 847 1,560 1,865 2,182 2,681 3,182 5,028 5,198 4,331
353 187 109 264 114 89 708 1,128 1,747 584 717 722
304 358 432 493 718 698 1,013 931 1,022 1,058 1,167 1,090
Total Liabilities 1,052 1,048 1,217 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183
268 344 397 547 708 799 993 1,158 1,552 1,788 1,798 2,398
CWIP 58 32 21 83 93 396 1,010 1,551 1,846 2,183 2,304 601
Investments 3 3 3 2 87 50 42 49 18 236 118 96
723 668 796 1,009 1,541 1,444 1,896 2,019 2,573 2,502 2,902 3,087
Total Assets 1,052 1,048 1,217 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
142 265 240 172 948 329 312 812 449 1,463 552 724
-56 -67 -81 -256 -307 -486 -884 -756 -731 -840 -372 -448
-45 -229 -151 87 -224 -129 503 59 155 -597 -217 -262
Net Cash Flow 41 -31 8 3 417 -286 -69 115 -127 26 -37 14

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 50 56 54 64 40 40 61 45 69 24 56 68
Inventory Days 133 143 159 196 266 269 302 356 417 431 406 315
Days Payable 108 129 148 166 264 213 313 237 220 194 178 145
Cash Conversion Cycle 75 70 65 94 42 96 51 164 266 261 283 237
Working Capital Days 61 59 50 71 49 72 93 64 118 94 118 119
ROCE % 29% 31% 44% 38% 66% 29% 22% 23% 24% 26% 11% 7%

Shareholding Pattern

Numbers in percentages

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023
72.97 69.77 69.78 69.48 69.48 69.48 69.48 69.61 69.61 69.61 69.61 69.61
7.30 7.03 6.96 6.56 6.41 5.52 5.89 6.02 5.94 5.32 4.99 4.55
7.10 9.43 10.14 10.97 11.25 11.42 11.61 11.74 12.15 12.55 12.76 13.32
12.63 13.76 13.12 12.99 12.86 13.58 13.03 12.63 12.30 12.52 12.64 12.53

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls